ASH 2023 CLL/Lymphoma Highlights – ALPINE, SEQUOIA, SWOG-S1826, POLARIX Update with Dr. Mazyar Shadman

August 24, 2024
Conferences ASH 2023
Conferences ASH 2023
Share This:

Key Points

ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)
SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma
POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study
Dr. Mazyar Shadman
Profile

American Society of Hematology (ASH) 2023 Conference

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective.

Tags:
Dr. Mazyar Shadman ASH 2023 CLL/Lymphoma

Related Posts

Conferences ESMO 2023 August 24, 2024
ESMO 2023 Lung Cancer Highlights – Keynote 671, ALINA, TropionLung01
Conferences ASH 2024 January 7, 2025
Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski

This website uses Cookies to ensure you receive the best experience.